

March 04, 2025

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: **JLHL**

To,
BSE Limited
P. J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: **543980**

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) - Intimation of incorporation of a Subsidiary Company

Dear Sir/Madam,

Pursuant to Regulation 30 of the Listing Regulations, we wish to inform you that Jupiter Pharmacy, a partnership firm in which the Company holds a 95% of partnership stake, has now been converted into Private Limited Company (without any change in the ownership structure).

The Central Registration Center has approved the conversion of Jupiter Pharmacy to Jupiter Hospital Pharmacy Private Limited (“JHPPL”) vide its letter dated March 03, 2025. Consequently, JHPPL will now be a subsidiary of Jupiter Life Line Hospitals Limited (“Holding Company/Company”) and there is no change in its holding pattern, beneficial ownership and activities.

The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is attached herewith as “**Annexure A**”

The same will be available on the website of the Company at www.jupiterhospital.com

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking you.

For JUPITER LIFE LINE HOSPITALS LIMITED,

Suma Upparatti
Company Secretary & Compliance Officer

Annexure-A

| Name of the target entity, details in brief such as size, turnover etc. | Name: Jupiter Hospital Pharmacy Private Limited CIN: - U46497MH2025PTC441784 Authorized Capital: ₹1,00,000 (Rupees One Lakhs) divided into 10,000 (Ten Thousand) equity shares of ₹10/- each Turnover of erstwhile entity: - Rs. 277.71 Million in FY 2023-24 | | | | | | | | |
|---|--|----------------|-------------------|-----------|--------|-----------|--------|-----------|--------|
| Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” | This is not an acquisition. It is merely conversion of partnership firm into a private limited company, without any finances being involved. | | | | | | | | |
| Industry to which the entity being acquired belongs; | Engaged in the business of “Pharmacy” | | | | | | | | |
| Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | Jupiter Hospital Pharmacy Private Limited (erstwhile M/s Jupiter Pharmacy) will be in the business of running OP pharmacy shops. No change in activity as a result of this conversion. | | | | | | | | |
| Brief details of any governmental or regulatory approvals required for the acquisition; | N/A | | | | | | | | |
| Indicative time period for completion of the acquisition; | N/A | | | | | | | | |
| Nature of consideration - whether cash consideration or share swap and details of the same; | N/A | | | | | | | | |
| Cost of acquisition or the price at which the shares are acquired | N/A | | | | | | | | |
| Percentage of shareholding / control acquired and / or number of shares acquired; | No Change. Company continues to hold 95% | | | | | | | | |
| Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years’ turnover, country in which the acquired entity has presence and any other significant information (in brief); | Line of Business of JHPPL: - Pharmacy shops. Country of Incorporation: - India Turnover of erstwhile entity: - <table border="1" data-bbox="853 1792 1412 1935"> <thead> <tr> <th>Financial Year</th> <th>Amount (Millions)</th> </tr> </thead> <tbody> <tr> <td>2023-2024</td> <td>277.71</td> </tr> <tr> <td>2022-2023</td> <td>194.60</td> </tr> <tr> <td>2021-2022</td> <td>207.35</td> </tr> </tbody> </table> | Financial Year | Amount (Millions) | 2023-2024 | 277.71 | 2022-2023 | 194.60 | 2021-2022 | 207.35 |
| Financial Year | Amount (Millions) | | | | | | | | |
| 2023-2024 | 277.71 | | | | | | | | |
| 2022-2023 | 194.60 | | | | | | | | |
| 2021-2022 | 207.35 | | | | | | | | |